Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2020; 8(19): 4488-4493
Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4488
Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4488
Extremely rare case of successful treatment of metastatic ovarian undifferentiated carcinoma with high-dose combination cytotoxic chemotherapy: A case report
Hong Beum Kim, Department of Premedical Course, Chosun University School of Medicine, Gwngju 505717, South Korea
Hee Jeong Lee, Sang-Gon Park, Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju 505717, South Korea
Ran Hong, Department of Pathology, Chosun University Hospital, Gwangju 505717, South Korea
Author contributions: Kim HB contributed to manuscript drafting; Hong R confirmed the pathology; Park SG advised manuscript drafting; Lee HJ proofread and revised the manuscript as a corresponding author; all authors issued final approval for the version to be submitted.
Supported by the National Research Foundation of Korea , funded by the Ministry of Science, ICT, and Future Planning, No. NRF-2017R1D1A1B04031741; and grants from the Chosun University Hospital, No. 2019 .
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Conflict-of-interest statement: The authors declare no conflict-of-interest.
CARE Checklist (2016) statement: The manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Hee Jeong Lee, MD, PhD, Assistant Professor, Doctor, Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, 365 Pilmun-daero, Dong-gu, Gwang-ju 505717, South Korea. hjangel21c@hanmail.net
Received: March 3, 2020
Peer-review started: March 3, 2020
First decision: July 25, 2020
Revised: August 9, 2020
Accepted: September 2, 2020
Article in press: September 2, 2020
Published online: October 6, 2020
Processing time: 208 Days and 23.4 Hours
Peer-review started: March 3, 2020
First decision: July 25, 2020
Revised: August 9, 2020
Accepted: September 2, 2020
Article in press: September 2, 2020
Published online: October 6, 2020
Processing time: 208 Days and 23.4 Hours
Core Tip
Core Tip: Palliative chemotherapy is the only available treatment for metastatic ovarian undifferentiated carcinoma. However, we used a high-dose combination chemotherapy of etoposide, ifosfamide, and cisplatin instead of the widely used paclitaxel and platinum and successfully treated an extremely rare case of inoperable metastatic ovarian undifferentiated carcinoma.